Singular Health Wins FDA Clearance for Cloud Platform in Just 40 Days

Singular Health (ASX: SHG) has secured FDA 510(k) clearance for its 3DICOM MD® Cloud platform, a Class II Software as a Medical Device (SaMD). The clearance, completed in 40 days compared to the typical 90-day review period, expands the company’s regulated product portfolio and strengthens its U.S. commercial strategy. The cloud-based platform removes hardware installation barriers and extends imaging modality support to include X-ray and ultrasound alongside CT, MRI, and PET scans.

The accelerated approval timeline reflects the quality of Singular Health’s regulatory submission. The clearance builds on the company’s October 2022 FDA approval for the desktop version of 3DICOM MD®, establishing a second regulated product in the U.S. market.

Singular Health Secures FDA 510(k) Clearance for Cloud-Based Medical Imaging Platform

The U.S. Food and Drug Administration granted 510(k) clearance for 3DICOM MD® Cloud, following a 40-day review process. This represents a material acceleration compared to standard review timelines, which typically span approximately 90 calendar days. The expedited clearance demonstrates regulatory submission quality and comprehensive validation testing.

Confirmation of lodgement was received on 29 November 2025. The cloud-based platform has been cleared as a Class II Software as a Medical Device (SaMD), enabling marketing and clinical use across U.S. healthcare organisations. This classification requires manufacturers to demonstrate substantial equivalence to a predicate device, in this case, the desktop version of 3DICOM MD® cleared in October 2022.

Browser-enabled deployment eliminates the need for hardware procurement and complex IT installations, removing traditional adoption barriers for healthcare facilities. The platform facilitates timely access to 3D medical imaging across multiple sites and multidisciplinary teams, addressing infrastructure challenges in image sharing.

Singular Health has expanded imaging modality coverage from three to five types. The cloud platform now supports CT, MRI, PET, X-ray, and ultrasound, broadening clinical applicability beyond the desktop version’s capabilities. X-ray and ultrasound represent high-volume, high-frequency imaging types, materially increasing addressable use cases.

CEO Commentary

“This clearance, achieved well ahead of time, represents a major milestone for Singular Health and our U.S. strategy. 3DICOM MD® Cloud removes many of the traditional barriers to adoption by eliminating the need for hardware and complex desktop installations, while expanding modality coverage to include X-ray and ultrasound. This positions the Company to scale faster and drive greater impact in reducing duplicate imaging,” said Denning Chong, Managing Director & CEO.

Key Clearance Highlights:

1. 40-day FDA review completed, well ahead of typical 90-day timeframe
2. Class II SaMD designation enables U.S. marketing and clinical deployment
3. Cloud-based architecture removes hardware and installation requirements
4. Expanded modality support adds X-ray and ultrasound to existing CT, MRI, PET coverage
5. Browser-enabled access improves usability across healthcare organisations

The regulatory submission leveraged the company’s established FDA clearance for the desktop version, enabling a streamlined pathway by building on a regulated foundation for image viewing and clinical use.

What Does FDA Clearance Mean for Singular Health Shareholders?

FDA 510(k) clearance is a regulatory approval that permits a medical device manufacturer to market and sell a Class II device in the United States. Class II devices are moderate-risk products that require manufacturers to demonstrate substantial equivalence to a legally marketed predicate device. For Singular Health (ASX: SHG), this clearance enables commercial sales of 3DICOM MD® Cloud to U.S. healthcare organisations.

The clearance positions (ASX: SHG) to scale faster in the U.S. healthcare market by addressing key adoption barriers. The desktop version, cleared in October 2022, required hardware installation and IT infrastructure coordination, creating friction in the sales process. The cloud platform eliminates these requirements through browser-based access, reducing deployment complexity for healthcare buyers.

Material differences between the desktop and cloud versions create distinct commercial advantages. Cloud deployment requires no local hardware, enabling faster implementation timelines. Browser-enabled access allows clinical teams to view and share imaging data from any location with internet connectivity, supporting multidisciplinary collaboration across facilities. Reduced IT complexity lowers the total cost of ownership for healthcare organisations, strengthening the value proposition for enterprise buyers.

The expanded modality coverage materially broadens clinical applicability. The desktop version supported three imaging types: CT, MRI, and PET. The cloud platform adds X-ray and ultrasound, two high-volume modalities that represent significant portions of daily imaging workflows in hospitals and diagnostic centres.

Supported Imaging Modalities:

• CT (Computed Tomography)
• MRI (Magnetic Resonance Imaging)
• PET (Positron Emission Tomography)
• X-ray
• Ultrasound

Cloud Deployment Advantages:

• No hardware procurement or installation required
• Browser-based access from any device
• Reduced IT infrastructure complexity
• Cross-site and multi-facility sharing capabilities
• Faster deployment timelines for healthcare organisations

The regulatory milestone provides validation required for enterprise healthcare sales. U.S. healthcare organisations purchasing medical imaging software require FDA clearance for compliance and clinical credibility. With two cleared products, Singular Health can now offer deployment flexibility based on customer IT infrastructure and workflow requirements.

Understanding Medical Imaging Software as a Medical Device (SaMD)

Software as a Medical Device (SaMD) refers to software intended for medical purposes that performs functions without being part of a physical hardware medical device. The FDA classifies SaMD products based on risk level, with Class II devices representing moderate risk requiring regulatory clearance before marketing.

FDA clearance matters for commercial credibility in the U.S. healthcare market because purchasing decisions at hospitals and health systems require regulatory compliance. Clinical software must demonstrate safety and effectiveness through the 510(k) pathway, which requires manufacturers to show substantial equivalence to a predicate device already cleared by the FDA.

Class II designation applies to moderate-risk devices that require special controls to provide reasonable assurance of safety and effectiveness. For medical imaging software, Class II classification indicates the product is used for diagnostic-quality image viewing and clinical decision support, but does not carry the higher risk associated with Class III devices such as implantable technologies.

3DICOM MD® Cloud fits this classification by enabling healthcare professionals to view, manipulate, and share diagnostic-quality medical images across CT, MRI, PET, X-ray, and ultrasound modalities. The platform does not alter the underlying imaging data but provides tools for 3D visualisation and communication between clinical teams.

510(k) Clearance Process:

1. Identify predicate device: Manufacturer identifies a legally marketed device with similar intended use and technological characteristics
2. Submit 510(k) application: Comprehensive documentation demonstrating substantial equivalence to predicate device
3. FDA review: Assessment of safety, effectiveness, and technological comparison (typical timeline: 90 days)
4. Clearance or additional information request: FDA grants clearance or requests further data

Predicate Device Definition

A predicate device is a legally marketed device to which a new device is compared in a 510(k) submission. The manufacturer must demonstrate that the new device is substantially equivalent in terms of intended use, technological characteristics, and performance. For 3DICOM MD® Cloud, the predicate device was the desktop version of 3DICOM MD® cleared in October 2022.

FDA clearance provides regulatory validation required for enterprise healthcare sales in the U.S., the world’s largest healthcare market by expenditure. SaMD classification positions Singular Health within the growing digital health regulatory framework, enabling participation in procurement processes at major hospital systems and health organisations.

What Is the Market Opportunity for Singular Health’s Cloud-Based Software?

The U.S. duplicate imaging market represents an estimated US$16.5 billion total addressable market (TAM) for reduction technologies. This figure is based on direct imaging costs of US$236.5 billion and an estimated 7.7% duplicate imaging rate across PET, CT, MRI, X-ray, and ultrasound modalities.

Duplicate imaging occurs when the same or similar diagnostic scans are repeated unnecessarily due to poor image sharing and accessibility between healthcare facilities and systems. The estimated duplicate imaging rate is informed by peer-reviewed research, including Bailey et al., Health Information Exchange and the Frequency of Repeat Medical Imaging, American Journal of Managed Care (2013), which reported a repeat imaging rate of approximately 7.7% in a large U.S. cohort. The Company’s estimated TAM is based on an internal market analysis applying modality-specific duplicate rates (approximately 4%–8.5%) to estimated annual U.S. scan volumes across X-ray, CT, MRI, PET and ultrasound, multiplied by average per-scan costs for each modality.

The addition of X-ray and ultrasound modalities materially expands Singular Health’s addressable market compared to the desktop version, which supported only CT, MRI, and PET. X-ray and ultrasound represent high-volume imaging types used across emergency departments, primary care, and diagnostic centres. X-ray is the most frequently performed imaging modality in healthcare, whilst ultrasound provides real-time imaging without ionising radiation, making it particularly valuable for paediatric and obstetric care.

Duplicate imaging creates dual inefficiencies: financial waste for healthcare systems and unnecessary radiation exposure for patients. Each repeated CT or X-ray scan exposes patients to additional ionising radiation, raising cumulative lifetime exposure risks. Healthcare organisations are financially incentivised to reduce unnecessary imaging through both direct cost savings and improved patient safety metrics.

3DICOM MD® Cloud addresses these inefficiencies by providing infrastructure for better image sharing across sites and clinical teams. The platform’s browser-based architecture enables authorised users to access existing imaging records from any location, reducing the likelihood of ordering repeat scans due to unavailable previous studies.

The TAM expansion from three modalities (desktop) to five modalities (cloud) significantly increases potential use cases and revenue opportunities. X-ray and ultrasound are performed more frequently than advanced imaging types, with X-ray representing the highest volume of diagnostic imaging procedures globally. This volume characteristic translates to more touchpoints for duplicate reduction and broader applicability across clinical pathways.

How Does 3DICOM MD® Cloud Reduce Duplicate Medical Imaging?

Duplicate imaging occurs primarily due to poor image sharing and access between healthcare facilities and clinical information systems. When physicians cannot readily access a patient’s previous imaging studies from other providers or facilities, they often order new scans rather than risk diagnostic delays. This pattern creates systemic inefficiency and unnecessary patient radiation exposure.

Cloud deployment improves accessibility by eliminating installation and hardware barriers. The browser-based architecture enables authorised clinical users to access imaging records from any device with internet connectivity, removing dependencies on specific workstations or local installations. Multi-site access allows specialists at different facilities to view the same imaging studies simultaneously, supporting coordinated care without requiring physical image transfer.

3D visualisation enhances clinical communication by providing advanced rendering tools that improve understanding of complex anatomical structures. When clinical teams can manipulate and view imaging data from multiple angles and perspectives, the need for additional scans to clarify diagnostic questions decreases. Enhanced visualisation supports more confident diagnostic decisions based on existing imaging data.

The platform functions as infrastructure rather than a point solution, integrating into existing clinical workflows without requiring wholesale system replacement. Healthcare organisations can deploy the cloud platform alongside existing Picture Archiving and Communication Systems (PACS), extending functionality rather than creating parallel workflows. This integration approach reduces adoption friction and preserves prior IT investments.

Key Cloud Platform Benefits:

• Browser-based access eliminates workstation dependencies
• No hardware procurement or installation timeline
• Cross-site sharing enables multi-facility collaboration
• 3D visualisation tools enhance diagnostic confidence
• Integration with existing PACS infrastructure

Cost savings for healthcare systems materialise through reduced imaging expenditure and improved operational efficiency. Each avoided duplicate scan represents direct savings on technologist time, equipment utilisation, and contrast agent costs. Patient outcomes improve through reduced cumulative radiation exposure, particularly important for paediatric populations and patients requiring serial imaging over time.

CEO Statement on Adoption Barriers

“3DICOM MD® Cloud removes many of the traditional barriers to adoption by eliminating the need for hardware and complex desktop installations, while expanding modality coverage to include X-ray and ultrasound. This positions the Company to scale faster and drive greater impact in reducing duplicate imaging,” said Denning Chong, Managing Director & CEO.

The infrastructure positioning creates value for enterprise buyers by addressing a measurable cost centre (duplicate imaging) whilst supporting broader strategic goals around care coordination and patient safety. Healthcare organisations purchasing medical imaging infrastructure prioritise solutions that integrate seamlessly, demonstrate regulatory compliance, and provide quantifiable return on investment through reduced operational costs.

U.S. Commercial Strategy and Next Steps

The FDA clearance strengthens Singular Health’s enterprise sales proposition for large U.S. healthcare organisations by expanding the regulated product portfolio to two distinct deployment options. The desktop version, cleared in October 2022, remains available for organisations preferring on-premises installations with direct hardware control. The cloud version provides an alternative pathway for organisations prioritising rapid deployment and reduced IT infrastructure requirements.

Dual-product strategy reduces sales friction by accommodating diverse customer IT policies and clinical workflow requirements. Academic medical centres with stringent data governance protocols may prefer desktop deployment with local data control. Community hospitals and diagnostic imaging centres seeking faster implementation timelines benefit from cloud deployment’s reduced technical complexity.

The 40-day accelerated review timeline demonstrates regulatory submission quality, reducing perceived risk for prospective customers evaluating the platform. Healthcare organisation procurement processes often include regulatory compliance assessment as a mandatory criterion. Expedited FDA clearance signals robust validation testing and documentation, strengthening confidence in product reliability.

Strategic Advantages of Dual-Product Portfolio:

1. Deployment flexibility accommodates diverse IT infrastructure requirements
2. Expanded customer base includes organisations with varying technical preferences
3. Reduced sales cycle friction through multiple pathway options
4. Regulatory validation across both deployment models
5. Scalability pathway from desktop to cloud as organisations evolve

Cloud Version Commercial Differentiators:

• Faster deployment timelines (no hardware procurement delay)
• Lower total cost of ownership (reduced IT maintenance requirements)
• Enhanced accessibility (browser-enabled multi-site access)
• Expanded modality coverage (X-ray and ultrasound inclusion)
• Simplified vendor management (cloud infrastructure handled by Singular Health)

Singular Health will continue to update the market on material commercial developments in line with continuous disclosure obligations. The company has not provided specific revenue guidance or customer acquisition targets in the announcement, maintaining focus on the regulatory milestone achieved and positioning for commercial execution in the U.S. healthcare market.

Want more Biotech and Healthcare insights?

Stay ahead in the fast-evolving biotech and healthcare sectors with the free Big News Blasts service. Join over 20,000 investors receiving breaking news and comprehensive analysis tailored exclusively to non-resource ASX sectors, including biotech innovations like Singular Health’s FDA-cleared medical imaging platform.

Don’t miss critical updates that could impact your portfolio — sign up now by clicking the “Free Alerts” button in the site header or banner to start receiving these expert insights from StockWire X.